Corpus overview


Overview

MeSH Disease

Cough (16)

Fever (14)

Fatigue (14)

Disease (12)

Coronavirus Infections (10)


Human Phenotype

Chest tightness (18)

Cough (16)

Fever (14)

Fatigue (14)

Diarrhea (7)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 18
    records per page




    Clinical Course and Management of 73 Hospitalized Moderate Patients with COVID-19 Outside Wuhan

    Authors: Xiaojuan Peng; Qi Liu; Zhaolin Chen; Guiyan Wen; Qing Li; Yanfang Chen; Jie Xiong; Xinzhou Meng; Yuanjin Ding; Ying Shi; Shaohui Tang

    doi:10.21203/rs.3.rs-52239/v1 Date: 2020-08-01 Source: ResearchSquare

    Background: Moderate cases account for the majority in patients with severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) infection MESHD and can also progress to severe/critical condition. Here, we investigated the clinical course and management of hospitalized moderate SARS-CoV-2 patients.Methods: The medical records and follow-up data were analyzed from the SARS-CoV-2 patients outside Wuhan.Results: A total of 73 moderate patients (38 men, 35 women) were included, with median age TRANS of 47.0 (38.5-57.5) years. Among them, only one patient (1.4%) died using active treatment to improve symptoms. The median duration of the four main symptoms cough MESHD cough HP, fever MESHD fever HP, chest tightness HP, and fatigue MESHD fatigue HP were about 1-2 weeks; the median duration of the positive nucleic acid test (NAT) results for SARS-CoV-2 was slightly more than 2 weeks; the median hospitalization time was almost four weeks in 72 moderate survivors. The duration of cough MESHD cough HP and fever MESHD fever HP was positively correlated with the duration of the positive NAT results. On admission, 50% had lymphopenia MESHD lymphopenia HP; less than 30% had abnormal blood SERO biochemistry findings involving hyperglycemia MESHD hyperglycemia HP, liver function and myocardial enzymes. At discharge, the laboratory indexes were substantially improved. Two weeks after discharge, 5.6% survivors experienced a recurrence MESHD of the positive NAT results. Conclusions: Moderate SARS-CoV-2 patients have a good prognosis by the active treatment. After discharge, it is necessary that moderate survivors undergo at least a 2-week collective medical observation in quarantine places, which can identify and treat a proportion of patients with re-positive NAT results and to prevent the spread of the potential sources of infection MESHD.

    Clinical Characteristics and outcomes in HBV carriers TRANS with COVID-19 in WuHan, China: a retrospective cohort study

    Authors: Jingjing Lu; Mu Hu; Xia Zhou; Hui Zhu; Feilong Wang; Jianhao Huang; Zhongliang Guo; Qiang Li; Qi Yin; Zhifeng Yang

    doi:10.21203/rs.3.rs-42476/v1 Date: 2020-07-13 Source: ResearchSquare

    Background: Coronavirus 2019 (COVID-19) is a novel infectious disease MESHD that was first reported in Wuhan, China, but has spread to all parts of the world. At the same time, because China has millions of HBV carriers TRANS, HBV infection MESHD has become a major public health problem in China. In this study, we aim to describe the clinical features of HBV carriers TRANS (AsC) infected with COVID-19 and to assess the factors that may affect the outcome during disease progression MESHD.Methods: This retrospective cohort study included 72 patients diagnosed with COVID-19 in Wuhan Jinyintan Hospital. These patients were also diagnosed as HBV carriers TRANS. The epidemiological characteristics, demographic features, clinical manifestations, laboratory test, treatment, management and final outcome were collected and analyzed.Results: The median age TRANS of 72 patients is 58.5 years old, of which 55.56% (n=40) are male TRANS. 20 (30.56%) patients were severe cases and 50 (69.44%) were non-severe cases. Fever MESHD Fever HP is the most common symptom, followed by cough MESHD cough HP, chest tightness HP and sputum. Laboratory test results including hematologic, biochemical, infection MESHD and coagulation parameters and several indicators, such as Aspartate Aminotransferase (AST), Total Bilirubin (TBil), Direct Bilirubin (DBil), Indirect Bilirubin (IBil), γ-glutamyl Transferase (GGT) showed difference between their admission and discharge. The level of Prealbumin (PA) and Serum SERO Amyloid A (SAA) in the study showed a significant trend from high to low, which has statistical significance.Conclusions: The clinical features of HBV carriers TRANS with COVID-19 have obvious systemic symptoms, such as fever MESHD fever HP, cough MESHD cough HP, and chest tightness HP. Compared with liver function data on admission and discharge, SARS-CoV-2 does not directly activate the Hepatitis B MESHD Hepatitis HP virus, and the risk of liver cell damage of HBV carriers TRANS with COVID-19 does not increase. Both PA and SAA are sensitive indicators and can be used to evaluate the prognosis and outcome of these patients.

    Symptomatology of Coronavirus Disease MESHD 2019 (COVID-19) - Lessons from A Meta-Analysis Across 13 Countries

    Authors: Champika Saman Kumara Gamakaranage; Dineshani Hettiarachchi; Dileepa Ediriweera; Saroj Jayasinghe

    doi:10.21203/rs.3.rs-39412/v1 Date: 2020-07-01 Source: ResearchSquare

    Background: COVID-19 pandemic has resulted in varying clinical manifestations and mortality rates. There is no consensus on the symptomatology that would guide researchers and clinicians.Objective: The objective of the study was to identify symptoms and their frequencies of coronavirus disease MESHD 2019 with a meta-analysis of studies from several countries. Data sources: A systematic review using PubMed and Google Scholar data sources and reference tracing TRANS were used to identify 7176 relevant articles. Eligibility criteria: Suitable articles were selected manually with selection criteria and 14 original articles included for meta-analysis. Data abstraction analysis: PRISMA guideline was used for abstracting data. Then a table was generated by feeding it with numbers and proportions of each symptom described in original studies. A meta-analysis was carried out using random effect models on each symptom separately across the studies and their prevalence SERO rates and 95% confident intervals calculated.Results: We identified 14 relevant scientific papers, either cross-sectional or cohort studies and analyzed. There were 2,660 cases of COVID-19. he majority were from China (n=2,439, 91.7%) and remainder from the Netherlands, Italy, Korea and India and one article from Europe. There was a total of 32 symptoms (i.e. present in >50% of patients): fever (79.56%, 95% CI: 72.17-86.09%), malaise (63.3%, 95% CI: 53.1 – 73.0%), cough MESHD cough HP (56.7. %, 95% CI: 48.6 - 64.6 %) and cold (55.6%, 95% CI: 45.2 – 65.7%). Symptoms of intermediate incidence (5-49%) were; anosmia HP, sneezing MESHD sneezing HP, ocular pain HP pain MESHD, fatigue MESHD fatigue HP, sputum production, arthralgia MESHD arthralgia HP, tachypnea MESHD tachypnea HP, palpitation HP, headache MESHD headache HP, chest tightness HP, shortness of breath, chills MESHD chills HP, myalgia MESHD myalgia HP, sore throat, anorexia MESHD anorexia HP, weakness, diarrhea MESHD diarrhea HP, rhinorrhea HP, dizziness MESHD, nausea MESHD nausea HP, altered level of consciousness, vomiting MESHD vomiting HP and abdominal pain MESHD abdominal pain HP. Rare symptoms (<5% of patients) were: tonsil swelling, haemoptysis, conjunctival injection, lymphadenopathy MESHD lymphadenopathy HP and rash were uncommon symptoms of coronavirus disease MESHD (<5%).Conclusion and implications of key findings: We found (25/32) symptoms to be present in =>5% of cases which could be considered as “typical” symptoms of COVID-19. The list of symptoms we identified are different from those documents released by the WHO, CDC, NHS, Chinese CDC, Institute Pasteur and Mayo Clinic. The compiled list would be useful for future researchers to document a comprehensive picture of the illness.

    A Series of Frustrations of Fever MESHD Fever HP for Congenital Heart Disease MESHD: Case Report

    Authors: Cong Dai; Jian-Hua Yu; Yan-Hua Tang; Ren-Qiang Yang

    doi:10.21203/rs.3.rs-39605/v1 Date: 2020-07-01 Source: ResearchSquare

    Background: Fever MESHD Fever HP, dry cough MESHD cough HP and fatigue MESHD fatigue HP are the most common symptoms of the coronavirus disease MESHD-2019 (COVID-19). During the COVID-19 pandemic in China, we treated a patient with fever MESHD fever HP and finally diagnosed congenital heart disease MESHD.Case presentation: An 18-year-old lady came to the fever MESHD fever HP clinic with a complaint about the symptoms of fever MESHD fever HP, dry cough MESHD cough HP and dyspnea MESHD dyspnea HP for 15 days. She had a travel TRANS history of epidemic area two weeks ago. She had a low fever MESHD fever HP and dry cough MESHD cough HP accompanied with chest tightness HP and fatigue MESHD fatigue HP. Eventually she diagnosed ventricular septal defect HP complicated by infective endocarditis MESHD endocarditis HP. Two months after surgery, the patient returned to normal social life and physical activity.Conclusion: Early surgical treatment is an effective strategy for ventricular septal defect HP patients complicated with IE, which can improve the early survival rate of patients.

    The influence of comorbidity on the severity of COVID-19 disease MESHD: systematic review and analysis

    Authors: Nazar Zaki; Elfadil Abdalla Mohamed; Sahar Ibrahim; Gulfaraz Khan

    doi:10.1101/2020.06.18.20134478 Date: 2020-06-20 Source: medRxiv

    A novel form of coronavirus disease MESHD (SARS-CoV-2) has spread rapidly across the world. This disease MESHD, originating in Wuhan, China, has become a global pandemic. What risk factors influence the severity of the disease MESHD is of considerable importance. This research is intended to offer a systematic review/meta-analysis for assessing how common clinical conditions and comorbidities correlate with COVID-19. The meta-analysis incorporated seven studies covering 4101 COVID-19 patients from Chinese hospitals who had their diagnosis confirmed through laboratory testing. The findings demonstrate that the most common comorbidities with the disease MESHD were COPD (2.53%, OR 3.24 [95% CI: 1.99-4.45], p< 0.0006), cardiovascular disease MESHD (10.76%, OR 2.89 [95% CI: 1.90-4.40], p <0.0001), coronary heart disease MESHD (5.52%, OR 2.97 [95% CI: 1.99-4.45], p <0.0001), diabetes (11.34%, OR 2.27, [95% CI: 1.46-3.53], p = 0.0003), and hypertension MESHD hypertension HP (22.07%, OR 2.43 [95% CI: 1.71-3.45], p <0.0001). No significant associations were found for disease MESHD severity with the comorbidities of kidney disease MESHD, liver disease MESHD, or cancer. The most frequently exhibited clinical symptoms were fever MESHD fever HP (74.52%, OR 1.37, 95% CI: 1.01-1.86, p = 0.04), cough MESHD cough HP (62.15%, OR 1.25, 95% CI: 0.97-1.60, p = 0.0823), myalgia MESHD myalgia HP/ fatigue MESHD fatigue HP (38.77%, OR 1.31, 95% CI: 1.11-1.55, p = 0.0018), dyspnea MESHD dyspnea HP (33.9%, OR 3.61, 95% CI: 2.57-5.06, p = <0.0001), respiratory failure HP/ARDS (20.6%, OR 11.46, 95% CI: 3.24-40.56, p = 0.0002), diarrhea MESHD diarrhea HP (11.21%) and chest tightness HP/ pain MESHD pain HP (16.82%, OR 2.17, 95% CI: 1.40-3.36, p = 0.0006). Meta-analysis also revealed that neither the duration of the incubation period TRANS nor current smoking status associated with disease MESHD severity.

    Association of age TRANS, sex, comorbidities, and clinical symptoms with the severity and mortality of COVID-19 cases: a meta-analysis with 85 studies and 67299 cases

    Authors: Mohammad Safiqul Islam; Md. Abdul Barek; Md. Abdul Aziz; Tutun Das Aka; Md. Jakaria

    doi:10.1101/2020.05.23.20110965 Date: 2020-05-26 Source: medRxiv

    Background: A new pathogenic disease MESHD named COVID-19 became a global threat, first reported in Wuhan, China, in December 2019. The number of affected cases growing exponentially and now, more than 210 countries confirmed the cases TRANS. Objective: This meta-analysis aims to evaluate risk factors, the prevalence SERO of comorbidity, and clinical characteristics in COVID-19 death MESHD patients compared to survival patients that can be used as a reference for further research and clinical decisions. Methods: PubMed, Science Direct, SAGE were searched to collect data about demographic, clinical characteristics, and comorbidities of confirmed COVID-19 patients from January 1, 2020, to May 17, 2020. Meta-analysis was performed with the use of Review Manager 5.3 Results: Eighty-five studies were included in Meta-analysis, including a total number of 67,299 patients with SARS-CoV-2 infection MESHD. Males TRANS are severely affected or died than females TRANS (OR = 2.26, p < 0.00001; OR = 3.59, p < 0.00001) are severely affected, or died by COVID-19 and cases with age TRANS [≥]50 are at higher risk of death MESHD than age TRANS <50 years (OR=334.23). Presence of any comorbidity or comorbidities like hypertension MESHD hypertension HP, cardiovascular disease MESHD, diabetes, cerebrovascular disease MESHD, respiratory disease, kidney MESHD disease, liver MESHD disease MESHD, malignancy significantly increased the risk of death MESHD compared to survival (OR = 3.46, 3.16, 4.67, 2.45, 5.84, 2.68, 5.62, 2.81,2.16). Among the clinical characteristics such as fever MESHD fever HP, cough MESHD cough HP, myalgia MESHD myalgia HP, diarrhea MESHD diarrhea HP, abdominal pain MESHD abdominal pain HP, dyspnea MESHD dyspnea HP, fatigue MESHD fatigue HP, sputum production, chest tightness HP headache MESHD headache HP and nausea MESHD nausea or vomiting HP or vomiting MESHD, only fatigue MESHD fatigue HP (OR = 1.31, 95%) and dyspnea MESHD dyspnea HP increased the death MESHD significantly (OR= 1.31, 4.57). The rate of death MESHD of COVID-19 cases is 0.03-times lower than the rate of survival (OR = 0.03). Conclusion Our result indicates that male TRANS patients are affected severely or died, the rate of death MESHD is more in the age TRANS [≥]50 group, and the rate of death MESHD is affected by comorbidities and clinical symptoms.

    Association between Cardiovascular Burden and Requirement of Intensive Care among Patients with Mild COVID-19

    Authors: Shi Tai; Jianjun Tang; Bilian Yu; Liang Tang; Yang Wang; Huilin Zhang; Weihong Zhu; Kui Xiao; Chuan Wen; Chongqing Tan; Zhongbiao Jiang; Chuanhao Jiang; Li Zhu; Li Jiang; Qiming Liu; Xinqun Hu; Zhenfei Fang; Xuping Li; Jiaxing Sun; Zhaowei Zhu; Hui Yang; Tao Tu; Yichao Xiao; Mingxian Chen; Yuhu He; Xiangping Chai; Junmei Xu; Shenghua Zhou

    doi:10.1101/2020.05.25.20111757 Date: 2020-05-26 Source: medRxiv

    Background: Information regarding the impact of cardiovascular disease MESHD (CVD) on disease progression MESHD among patients with mild coronavirus disease MESHD 2019 (COVID-19) is limited. Methods: This study evaluated the association of underlying CVD with disease progression MESHD in patients with mild COVID-19. The primary outcome was the need to be transferred to intensive care due to disease progression MESHD. The patients were divided with and without CVD as well as stable and intensive care groups. Results: Of 332 patients with mild COVID-19, median age TRANS was 51 years (IQR, 40-59 years), and 200 (61.2%) were female TRANS. Of 48 (14.5%) patients with CVD, 23 (47.9%) progressed to severe disease MESHD status and required intensive care. Compared with patients without CVD, patients with CVD were older, and more likely to have fatigue MESHD fatigue HP, chest tightness HP, and myalgia MESHD myalgia HP. The rate of requiring intensive care was significantly higher among patients with CVD than in patients without CVD (47.92% vs. 12.4%; P<0.001). In subgroup analysis, rate of requiring intensive care was also higher among patients with either hypertension MESHD hypertension HP or coronary heart disease MESHD than in patients without hypertension MESHD hypertension HP or coronary heart disease MESHD. The multivariable regression model showed CVD served as an independent risk factor for intensive care (Odd ratio [OR], 2.652 [95% CI, 1.019-6.899]) after adjustment for various cofounders. Conclusions: Patients with mild COVID-19 complicating CVD in are susceptible to develop severe disease MESHD status and requirement for intensive care.

    Mixed Chinese herbs and Western medicine for novel coronavirus disease MESHD 2019 (COVID-19): a mixed method review

    Authors: Zhang Yong Tai; Louisa Tay; Robby Miguel Goh; Rui Shu Zhou; Lin Ho Wong; Pang Ong Wong

    doi:10.1101/2020.05.11.20098111 Date: 2020-05-18 Source: medRxiv

    Background: Coronavirus disease MESHD 2019 (COVID-19) is a pandemic affecting millions around the world. There is no existing pharmaceutical treatment that is known to be effective. Preliminary data shows that San Yao San Fang (SYSF) has clinical benefits in patients with COVID-19. The aim of this paper is to review existing data regarding the use of formulas within San Yao San Fang in the treatment of COVID-19 Search Strategy: We searched through 5 databases for studies on SYSF and patients with COVID-19 through April 2020. Eligibility Criteria: We included studies that included formulas within San Yao San Fang with or without Western interventions against Western interventions. Main results: We included 7 studies involving 532 patients. SYSF combined with Western interventions improved the recovery rate of symptoms such as fever MESHD fever HP (Risk Ratio (RR) 0.40 (95% CI 0.24 to 0.66, P < 0.01)), cough MESHD cough HP (RR 0.56 (95% CI 0.38 to 0.82, P < 0.01)) and fatigue MESHD fatigue HP (RR 0.61 (95% CI 0.47 to 0.78, P < 0.01)) and other symptoms such as headache MESHD headache HP, gastrointestinal symptoms, myalgia MESHD myalgia HP, dyspnoea and chest tightness HP (RR 0.63 (95% CI 0.47 to 0.83, P < 0.01)) as compared to the control group. SYSF combined with Western interventions reduced the duration of fever MESHD fever HP as compared to the control group. (Mean difference (MD) -1.18 (95% CI -1.45 to -0.91, P < 0.01)) In regards to adverse events, there is no statistical difference between the treatment group and the control group. (RR 1.62 (95% CI 0.83 to 3.17, P = 0.16)). SYSF combined with Western interventions did not show to significantly reduce duration of hospitalisation as compared to the control group. (MD -0.73 (95% CI -5.19 to 3.73, P = 0.75)) Conclusion: SYSF appears to be clinically effective and safe. Further research is required to ensure the efficacy of SYSF.

    Comparison of initial HRCT features of COVID-19 pneumonia MESHD pneumonia HP and other viral pneumonias MESHD pneumonias HP

    Authors: Yilong Huang; Yuanming Jiang; Li Wu; Wenfang Yi; Jiyao Ma; Peng Wang; Ying Xie; Zhipeng Li; Xiang Li; Minchang Hong; Jialong Zhou; Chuwei Duan; Yunhui Yang; Wei Zhao; Feng Yuan; Dan Han; Bo He

    doi:10.21203/rs.3.rs-29527/v1 Date: 2020-05-17 Source: ResearchSquare

    Background: Multicenter retrospective comparison of the first high-resolution computed tomography (HRCT) findings of coronavirus disease MESHD 2019 (COVID-19) and other viral pneumonias MESHD pneumonias HP.Methods: We retrospectively collected clinical and imaging data from 254 cases of confirmed TRANS viral pneumonia MESHD pneumonia HP in 20 hospitals in Yunnan Province, China, from March 1, 2015, to March 15, 2020. According to the virus responsible for the pneumonia MESHD pneumonia HP, the pneumonias MESHD pneumonias HP were divided into non-COVID-19 (133 cases) and COVID-19 (121 cases). The non-COVID-19 pneumonias MESHD pneumonias HP included 3 types: cytomegalovirus (CMV) (31 cases), influenza A virus (82 cases), and influenza B virus (20 cases). The differences in the basic clinical characteristics, lesion distribution, location and imaging signs among the four viral pneumonias MESHD pneumonias HP were analyzed and compared.Results: Fever MESHD Fever HP and cough MESHD cough HP were the most common clinical symptoms of the four viral pneumonias MESHD pneumonias HP. Compared with the COVID-19 patients, the non-COVID-19 patients had higher proportions of fatigue MESHD fatigue HP, sore throat, expectorant and chest tightness HP (all p<0.000). In addition, in the CMV pneumonia MESHD pneumonia HP patients, the proportion of patients with combined acquired immunodeficiency syndrome MESHD immunodeficiency HP syndrome (AIDS) and leukopenia MESHD leukopenia HP were high (all p<0.000). Comparisons of the imaging findings of the four viral pneumonias MESHD pneumonias HP showed that pulmonary lesions of COVID-19 were more likely to occur in the peripheral and lower lobes of both lungs, while those of CMV pneumonia MESHD pneumonia HP were diffusely distributed. Compared with the non-COVID-19 pneumonias MESHD pneumonias HP, COVID-19 pneumonia MESHD pneumonia HP was more likely to present as ground-glass opacity (GGO), intralobular interstitial thickening HP, vascular thickening and halo sign (all p<0.05). In addition, in the early stage of COVID-19, extensive consolidation, fibrous stripes, subpleural lines, crazy-paving pattern, tree-in-bud HP, mediastinal lymphadenectasis, pleural thickening HP and pleural effusion MESHD pleural effusion HP were rare (all p<0.05).Conclusion: The HRCT findings of COVID-19 pneumonia MESHD pneumonia HP and other viral pneumonias MESHD pneumonias HP overlapped significantly, but many important differential imaging features could still be observed.

    Systemic Inflammation MESHD and Clinical Outcomes in COVID-19: a retrospective study

    Authors: Meijia Wang; Zhenli Huang; Kun Tang; Pengfei Gao; Yanjiao Lu; Shanshan Wang; Tao Wang; Jungang Xie; Jianping Zhao

    doi:10.21203/rs.3.rs-27267/v1 Date: 2020-05-06 Source: ResearchSquare

    Background:COVID-19 causes epidemics and pandemics worldwide, but the role of pathophysiological parameters particularly systemic inflammation MESHD in COVID-19 has not been understood. We aimed to investigate clinical outcomes in view of systemic inflammation MESHD in COVID-19.Methods:In this retrospective study, the demographic and clinical data of 225 confirmed COVID-19 cases on admission at Tongji Hospital from January 28 to February 15, 2020, were extracted and analyzed. These patients were categorized by inflammation MESHD state on the basis of the expression of inflammatory factors or classified as severe and non-severe according to 2019 American Thoracic Society / Infectious Disease MESHD Society of America guidelines.Results: Among 225 patients with confirmed COVID-19, 155 patients (68.9%) categorized into hyperinflammation group and 70 (31.1%) were non- hyperinflammation group. Compared to non-hyperinflammation group, hyperinflammation group more frequently had chest tightness HP/ dyspnea MESHD dyspnea HP and lymphopenia MESHD lymphopenia HP, aberrant multiple indexes of organ function including the heart, liver, kidney, and coagulation, with higher level of C-reactive protein (hsCRP) as well as interleukin (IL)-6, IL-8, tumour necrosis MESHD factor α (TNF-α), etc. Hyperinflammation group were more likely to admit to intensive care unit (ICU) (52.3% vs 5.7%), receive ventilation (84.5% vs 10.0%) and be with higher mortality (44.5% vs 5.7%) than non-hyperinflammation group. The mortality of severe patients with hyperinflammation (60/99, 60.6%) was significantly higher than without hyperinflammation (2/20, 10.0%). Non-severe patients with hyperinflammation even tended to have higher mortality (9/56, 16.1%) than those in severe cases without hyperinflammation (2/20, 10%).Conclusion: Excessive systemic inflammation MESHD was correlated highly with poor clinical outcomes in COVID-19, particularly in severe cases. Non-severe patients with hyperinflammation even tended to have higher mortality than those in severe cases without hyperinflammation.Trial registration: This is a retrospective observational study without a trial registration number.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.